1 / 25

Adult Medical-Surgical Nursing

Adult Medical-Surgical Nursing. Haematology Module: Leukaemia (lecture 1) Chemotherapy. Leukaemia: Description. A group of malignant disorders affecting: White blood cells (lymphocytes or granulocytes) Bone marrow Lymph system Spleen. Leukaemia: Characteristics.

mariko
Télécharger la présentation

Adult Medical-Surgical Nursing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Adult Medical-Surgical Nursing Haematology Module: Leukaemia (lecture 1) Chemotherapy

  2. Leukaemia: Description • A group of malignant disorders affecting: • White blood cells (lymphocytes or granulocytes) • Bone marrow • Lymph system • Spleen

  3. Leukaemia: Characteristics • Uncontrolled abnormal white cell division in the bone marrow: • → increased number of dysfunctional white blood cells: • Immature blast cells • Mature but dysfunctional cells • It is a systemic malignant disease: • There is no primary tumour and metastases

  4. Leukaemia: Aetiology • Both genetic and environmental factors involved

  5. Leukaemia Aetiology: Genetic Propensity • Oncogenes: • Chromosome changes from normal to abnormal genes

  6. Leukaemia Aetiology: Environment • Oncogenes are triggered or enhanced by exposure (even prenatal) to: • Chemical agents (benzene, dyes) • Radiation • Environmental pollutants • Smoking • Drugs of addiction • Viruses • (Immunological deficiencies expose further)

  7. Leukaemia: Classification • Myeloid Leukaemia: affects granulocytes (from myeloid stem cells) • Lymphocytic Leukaemia: affects lymphocytes (from lymphoid stem cells) • May be: • Acute (blast cells) • Chronic (mature but dysfunctional cells)

  8. Leukaemia: Classification • Acute Myelogenous Leukaemia (AML) • Acute Lymphocytic Leukaemia (ALL) • Chronic Myelogenous Leukaemia (CML) • Chronic Lymphocytic Leukaemia (CLL)

  9. Acute Myelogenous Leukaemia (AML)

  10. AML: Description • 85% of acute leukaemia incidence in adults • Acute onset • Proliferation of myeloblasts, immature granulocytes in the blood circulation

  11. AML: Pathophysiology • Uncontrolled abnormal cell division leading to: • Immature dysfunctional myeloblasts crowd the bone marrow and circulation • Infiltrate lymph nodes, spleen, liver, central nervous system • → node enlargement, lymphadenopathy, splenomegaly, hepatomegaly • Crowding out of normal erythroblast and platelet development in bone marrow: ↓ RBC and platelet count

  12. AML: Clinical Manifestations • Sudden onset • Patient is very susceptible to infection: • Prone to opportunistic infection as Candida Albicans • Fatigue • Pallor • Bleeding tendency • Bone pain: damaged overcrowded marrow

  13. AML: Diagnosis • CBC • Blood film: • Extremely ↑ number of immature white cells (myeloblasts) and ↓ RBC and platelets • Bone marrow biopsy: crowding of myeloblasts • Lumbar puncture • CT scan for evidence of leukaemia outside blood or bone marrow

  14. AML: Aims of Treatment • Induce remission (disease control), that is no evidence of the disease : • Blood and bone marrow appear normal (<5% blast cells) • Achieved by chemotherapy • If relapse occurs, must restart the whole treatment regime • Becomes ↑ more difficult to attain remission or cure • May get partial remission (evidence of disease in bone marrow still)

  15. Chemotherapy

  16. Chemotherapy • The treatment of choice for Leukaemia • Uses different combinations of drugs to destroy malignant cells

  17. Chemotherapy: Multiple Drug Protocol • A multiple drug regime or protocol: • Interrupts cell growth and division at different stages of the cell cycle • Therefore it is more effective • Minimises toxicity from high doses of a single agent • Reduces drug resistance

  18. Chemotherapy Protocols • Protocols have acronyms: as COAP • Cyclophosphamide • Oncovan • Arabinoside • Prednisone • Each drug taken singly or with another has a specific action on bone marrow cells

  19. Stages of Chemotherapy • There are three stages or phases of chemotherapy: • Induction phase • Intensification (consolidation or sanctuary phase) • Maintenance

  20. Chemotherapy: Induction Phase • Aggressive treatment: • Uses multiple drug protocol • Seeks to destroy malignant cells in: • Blood • Tissues • Bone marrow • Aims to achieve remission (< 5% blasts in bone marrow)

  21. Intensification/ Consolidation Phase • After remission achieved: • Immediate intensive treatment for several months • Aims to eliminate remaining leukaemic cells • Includes intra-thecal chemotherapy (sanctuary phase) if leukaemic cells cross blood-brain barrier (ALL)

  22. Chemotherapy: Maintenance • Low doses of chemotherapy continued for years • Follow-up until declared cured

  23. Leukaemia: Adjuvant Therapy • Steroids • Sedatives and anti-emetics (Haloperidol, Cyclizine) • Blood transfusions • Neupogen (encourages leukopoiesis) • Bone marrow transplant depends on histocompatibility of donor and recipient • Bone marrow transplant follows remission • Success rate for bone marrow transplant is still quite low

  24. Chemotherapy: Toxic Effects • Toxicity to veins and local tissues/ may cause local tissue excoriation • Nephrotoxicity/ cardio- / hepatotoxicity • Nausea and vomiting • Alopecia • Compromised immune response: • Infection risk (isolation) • Reduced erythropoiesis (anaemia) • Reduced platelet production (bleeding tendency)

  25. Chemotherapy: Nursing Responsibilities • Preparation: • Gown, double gloves, eye goggles • Designated preparation cupboard • Double-checking • Patient preparation: • Adequate blood count, patient information • Administration: fluid pre-load, pre-medication • IV monitoring, close observation of site • Emotional and physical support throughout and in the community

More Related